u/gustav_solberg

research-use-only material is not approved for human use

the ICB decides the threshold and they are not the same across England

private prescription pricing moves monthly and the pharmacy is most of the spread

Two years and four months on a tier 3 list. Referral date and every letter kept, which turned out to matter when the service reorganised.

That is Scotland’s arrangement and the post is asking about England.

Kept a log from week one and the single most useful column turned out to be waist, not weight.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

WXT sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.

Resolution between two peaks depends on retention, selectivity and efficiency. A shallower gradient buys retention and usually resolution, at the cost of peak width and run time.

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

retention time alone is not identity

GL Biochem sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.

Not convinced. That is the New Zealand position and the thread is asking about Australia.

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

lead times on unusual lines are the thing to confirm up front

That figure cannot be quoted to two decimals off that baseline. The precision is not in the data.

NHS pathway or private prescription?

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

PBS listing and TGA registration are two different questions

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

First month I lost almost nothing and nearly quit. Month two and three were where it all happened.

Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.

Pharmacy-level availability and national supply are different questions: a pharmacy can be out while the wholesaler is not, and the pharmacist can check in minutes.

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chem

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

phase 3 is where the comparison becomes fair

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Sent the same vial to VendorInvestigate and Medutest. 98.1% against a claimed 98.0%. The difference was the gradient, not the material.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.

What reference standard was the assay run against?

Right, and comparing milligrams between a small molecule and a peptide is meaningless in either direction.

Strongly agree on protein. It did more for my muscle cramps than any of the things I bought to fix my muscle cramps.

Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.

BMI thresholds vary by ICB and by year

integration decisions move the number more than the sample does

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

axis labels or the trace is decoration

axis labels or the trace is decoration

area percent is relative to what the detector saw and nothing else

Push back: the compounded arrangements changed and the advice you are quoting predates the change.